Mylan Technologies Files Two Inter Partes Review Petitions Against Noven Pharmaceuticals

December 5, 2017 – Mylan Technologies, Inc. filed two inter partes review petitions to invalidate two of Noven Pharmaceuticals, Inc.’s patents on December 4, 2017 under both 35 U.S.C. §102 and §103 in the USPTO’s Patent Trial & Appeal Board. The patents are directed to monolithic transdermal drug delivery system for administering estradiol, and to conventional methods of making and administering them

The patent at issue in the first petition is U.S. Patent No. 9,724,310 entitled “Transdermal estrogen device and delivery”. The case is entitled Mylan Technologies, Inc., v. Noven Pharmaceuticals, Inc., Case No. IPR2018-00173. The patent at issue in the second complaint is U.S. Patent No. 9,730,900 entitled “Transdermal estrogen device and delivery”. The case is entitled Mylan Technologies, Inc., v. Noven Pharmaceuticals, Inc., Case No. IPR2018-00174.

By: Julian G. Pymento